Keytruda (Pembrolizumab) Price by US State (2026 Analysis)
Estimated Keytruda (Pembrolizumab) retail and out-of-pocket cost (per dose) across all 50 US states, compared with international pharmaceutical benchmarks in India (approx. $1,500). US state figures represent modeled healthcare-cost adjustments from the national baseline ($10,000).
State Price Variations for Keytruda (Pembrolizumab)
51 States & TerritoriesComplete State Cost Table
| State | US Price (Est.) | India Price | You Save |
|---|---|---|---|
| Alabama | $9,000 | $1,500 | $7,500 |
| Alaska | $12,800 | $1,500 | $11,300 |
| Arizona | $10,000 | $1,500 | $8,500 |
| Arkansas | $8,800 | $1,500 | $7,300 |
| California | $13,000 | $1,500 | $11,500 |
| Colorado | $10,800 | $1,500 | $9,300 |
| Connecticut | $12,200 | $1,500 | $10,700 |
| Delaware | $10,500 | $1,500 | $9,000 |
| Florida | $10,200 | $1,500 | $8,700 |
| Georgia | $9,600 | $1,500 | $8,100 |
| Hawaii | $13,200 | $1,500 | $11,700 |
| Idaho | $9,500 | $1,500 | $8,000 |
| Illinois | $10,600 | $1,500 | $9,100 |
| Indiana | $9,500 | $1,500 | $8,000 |
| Iowa | $9,300 | $1,500 | $7,800 |
| Kansas | $9,200 | $1,500 | $7,700 |
| Kentucky | $9,000 | $1,500 | $7,500 |
| Louisiana | $9,300 | $1,500 | $7,800 |
| Maine | $10,600 | $1,500 | $9,100 |
| Maryland | $11,800 | $1,500 | $10,300 |
| Massachusetts | $12,800 | $1,500 | $11,300 |
| Michigan | $9,800 | $1,500 | $8,300 |
| Minnesota | $10,600 | $1,500 | $9,100 |
| Mississippi | $8,600 | $1,500 | $7,100 |
| Missouri | $9,200 | $1,500 | $7,700 |
| Montana | $9,800 | $1,500 | $8,300 |
| Nebraska | $9,400 | $1,500 | $7,900 |
| Nevada | $10,200 | $1,500 | $8,700 |
| New Hampshire | $11,200 | $1,500 | $9,700 |
| New Jersey | $12,200 | $1,500 | $10,700 |
| New Mexico | $9,400 | $1,500 | $7,900 |
| New York | $13,000 | $1,500 | $11,500 |
| North Carolina | $9,600 | $1,500 | $8,100 |
| North Dakota | $9,700 | $1,500 | $8,200 |
| Ohio | $9,600 | $1,500 | $8,100 |
| Oklahoma | $8,900 | $1,500 | $7,400 |
| Oregon | $11,000 | $1,500 | $9,500 |
| Pennsylvania | $10,400 | $1,500 | $8,900 |
| Rhode Island | $11,400 | $1,500 | $9,900 |
| South Carolina | $9,500 | $1,500 | $8,000 |
| South Dakota | $9,500 | $1,500 | $8,000 |
| Tennessee | $9,200 | $1,500 | $7,700 |
| Texas | $10,000 | $1,500 | $8,500 |
| Utah | $10,000 | $1,500 | $8,500 |
| Vermont | $11,200 | $1,500 | $9,700 |
| Virginia | $10,600 | $1,500 | $9,100 |
| Washington | $11,800 | $1,500 | $10,300 |
| Washington, D.C. | $13,400 | $1,500 | $11,900 |
| West Virginia | $9,000 | $1,500 | $7,500 |
| Wisconsin | $10,000 | $1,500 | $8,500 |
| Wyoming | $9,800 | $1,500 | $8,300 |
Frequently Asked Questions: Keytruda (Pembrolizumab) Pricing
Why do Keytruda (Pembrolizumab) prices differ across US states?+
Prescription drug prices in the US vary by state due to differing pharmacy dispensing fee regulations, state tax laws, regional wholesale distribution costs, and varying health insurance plan coverage formularies. Out-of-pocket prices can differ by hundreds of dollars even between neighboring states.
How does the US price of Keytruda (Pembrolizumab) compare to international prices?+
In the United States, Keytruda (Pembrolizumab) averages approximately $10,000 per dose. In India, certified manufacturers produce equivalent formulations and authorized generics for about $1,500 per dose — saving patients up to 90%+ without compromising therapeutic equivalence.
Are generic or biosimilar versions of Keytruda (Pembrolizumab) available?+
Depending on patent expiry schedules, authorized generic alternatives and international equivalents may be accessible through licensed personal importation channels.
Other Cancer Medications
Gleevec (Imatinib)
Gleevec (imatinib) is a pioneering oral targeted therapy (a tyrosine kinase inhibitor) used to treat chronic myeloid leukemia and gastrointestinal stromal tumors. It transformed certain cancers into manageable chronic conditions. India was central to making low-cost generic imatinib widely available, and a month's supply there costs a tiny fraction of the US branded price.
Revlimid (Lenalidomide)
Revlimid (lenalidomide) is an oral targeted therapy used to treat multiple myeloma, myelodysplastic syndromes, and certain lymphomas, often taken in monthly cycles. Its US cost is among the highest of any oral cancer drug. Generic lenalidomide manufactured in India reduces the monthly cost by well over 95%.